By Top Class Actions  |  November 9, 2012

Category: Pharmaceuticals
{loadposition actos_lawsuit}
Follow us on Twitter and Facebook for the latest Actos Class Action Lawsuit & Settlement News!

 

Actos Side Effects Partially Explain 46% Sales Drop

By John Curran

 

Actos lawsuitIf Takeda Pharmaceutical was a person, it would be feeling the same pain as Actos bladder cancer sufferers. The firm faces hundreds of cases in federal court, with more being consolidated from claims by Actos multi-district litigation (MDL) attorneys. And the money is slowing to a trickle.

It was partly to be expected, though. While Actos side effects are already costing the company money, other pharmaceutical manufacturers were eager to jump in on the Type 2 diabetes drug. It became available in generic form over the summer (chemical name: pioglitazone), with three manufacturers trying to maximize profits during a six-month window. After that, in spite of significant Actos bladder cancer risks, nearly every generic maker will put Actos on the market.

That hurts Takeda Pharmaceutical over the long-term. It is shocking how much of an impact it is having over the short term. Consider that from May 1 to the end of September, sales dropped by nearly half. Its exclusivity period has only been lost for about a month and they are being hurt badly. It doesn’t help, of course, that Actos MDL attorneys are bringing attention to bladder cancer and other severe risks.

Still, those figures need context. Takeda still made more than half a billion dollars, using conservative estimates. What is more important is for people who may now be able to afford the medication to understand the real risks of Actos bladder cancer conditions. It is already banned in several countries, and at the low end has a 40 percent higher risk of causing bladder cancer than placebo.

The most recent study says that Actos side effects double the risk of bladder cancer compared to the average person and was published in the prestigious British Medical Journal. In spite of that, the FDA is still letting companies milk the Actos cash cow, in spite of numerous studies to the contrary.

There is help for those have been impacted by Actos side effects. Get started at our Actos Bladder Cancer Class Action Lawsuit Investigation. When you fill out the short form there, an experienced pioglitazone lawsuit lawyer will contact you to review the facts of your case. You may be eligible to pursue a claim against Takeda Pharmaceutical or one of the generic manufacturers.

It costs you nothing, but may offer you the peace of mind you deserve. Find out whether becoming a plaintiff makes sense, and contact one of our partner pioglitazone lawsuit lawyers now.

 

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.

 

Updated November 9th, 2012

 

All medical device, dangerous drug and medical class action and lawsuit news updates are listed in the Drug and Medical Device section of Top Class Actions.

 

LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement
©2008 – 2012 Top Class Actions® LLC
Various Trademarks held by their respective owners.

One thought on Actos Side Effects Partially Explain 46% Sales Drop

Leave a Reply

Your email address will not be published. By submitting your comment and contact information, you agree to receive marketing emails from Top Class Actions regarding this and/or similar lawsuits or settlements, and/or to be contacted by an attorney or law firm to discuss the details of your potential case at no charge to you if you qualify. Required fields are marked *

Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.